Circulating levels of inflammatory parameters pentraxin-3, cyclophilin and heparin-binding epidermal growth factor-like growth factor in patients with ST-elevation myocardial infarction

References

• Assimes TL, Roberts R. Genetics: implications for prevention and management of coronary artery disease. JACC. 2016;68(25):2797–2818.
   Web of Science ®Google Scholar
• O’Gara P, Kushner F, Ascheim D. ACCF/AHA Guideline for the management of ST-elevation myocardial infarction: executive summary. J Am Coll Card. 2013;61:485–510.
   PubMed Web of Science ®Google Scholar
• Vargova K, Toth-Zsamboki E, Beres BJ. Circulating endothelial cell count, plasma vWF and soluble ICAM-1 levels following primary or elective percutaneous intervention. Atheroscl. 2008;198:366–372.
   PubMed Web of Science ®Google Scholar
• Agewall S, Daniel M, Eurenius L. Risk factors for myocardial infarction with normal coronary arteries and myocarditis compared with myocardial infarction with coronary artery stenosis. Angiology. 2012;63(7):500–503.
   PubMed Web of Science ®Google Scholar
• Agewall S, Beltrame JF, Reynolds HR, et al. WG on cardiovascular pharmacotherapy. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017;3:143–153.
   Google Scholar
• Helseth R, Solheim S, Opstad T, et al. The time profile of pentraxin 3 in patients with acute ST-elevation myocardial infarction and stable angina pectoris undergoing percutaneous coronary intervention. Med Inflam. 2014;2014:1.
   Web of Science ®Google Scholar
• Vuković-Dejanović V, Bogavac-Stanojević N, Spasić S, et al. Association of serum pentraxin-3 and high-sensitivity C-reactive protein with the extent of coronary stenosis in patients undergoing coronary angiography. J Med Biochem. 2014;33:1–10.
   Google Scholar
• Tornvall P, Gerbaud E, Behaghel A, et al. Myocarditis or “true” infarction by cardiac magnetic resonance in patients with a clinical diagnosis of myocardial infarction without obstructive coronary disease: a meta-analysis of individual patient data. Atheroscl. 2015;241(1):87–91.
   PubMed Web of Science ®Google Scholar
• Peri G, Introna M, Corradi D, et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102(6):636–641.
   PubMed Web of Science ®Google Scholar
• Haibo L, Xiaofang G, Yao K, et al. Pentraxin-3 predicts long-term cardiac events in patients with chronic heart failure. Bio Med Res Int. 2015;2015:817615.
   Google Scholar
• Knoflach M, Kiechl S, Mantovani A, et al. Pentraxin as a marker of advanced atherosclerosis. Results from Bruneck, ARMY and ARFY studies. PLoS One. 2012;7(2):e31474.
   PubMed Web of Science ®Google Scholar
• Nigro P, Pompilio G, Capogrossi MC. Cyclophilin A: a key player for human disease. Cell Death Dis. 2013;4(10):e888.
   PubMed Web of Science ®Google Scholar
• Yan J, Zang X, Chen R, et al. The clinical implications of increased cyclophilin A levels in patients with acute coronary syndromes. Clin Chim Acta. 2012;413(7–8):691–695.
   PubMed Web of Science ®Google Scholar
• Mehta VB, Zhou Y, Radulescu A, et al. HB-EGF stimulates eNOS expression and nitric oxide production and promotes eNOS dependent angiogenesis. Growth Factors. 2008;26(6):301.
   PubMed Web of Science ®Google Scholar
• Chalothorn D, Moore S, Zhang H, et al. Heparin-binding epidermal growth factor-like growth factor, collateral vessel development, and angiogenesis in skeletal muscle ischemia. ATVB. 2005;25(9):1884–1890.
   Web of Science ®Google Scholar
• Nakata A, Miyagawa J, Yamashita S, et al. Localization of heparin-binding epidermal growth factor-like growth factor in human coronary arteries. Circulation. 1996;94(11):2778–2786.
   PubMed Web of Science ®Google Scholar
• O’Rourke SA, Dunne A, Monaghan MG. The role of macrophages in the infarcted myocardium: orchestrators of ECM remodeling. Front Cardiovasc Med. 2019;6:1–9.
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other societies on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37(29):2315–2381.
   PubMed Web of Science ®Google Scholar
• World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–2194.
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
   PubMed Web of Science ®Google Scholar
• Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988;240(4857):1285.
   PubMed Web of Science ®Google Scholar
• Ushikoshi H, Takahashi T, Chen X, et al. Local overexpression of HB-EGF exacerbates remodelling following myocardial infarction by activating noncardiomyocytes. Lab Invest. 2005;85(7):862–873.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Masamura K, Yoshida M, et al. A role of heparin-binding epidermal growth factor-like growth factor in cardiac remodelling after myocardial infarction. Biochem Biophys Res Comm. 2002;297(2):375–381.
   PubMed Web of Science ®Google Scholar
• Nigro P, Satoh K, O'Dell MR, et al. Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice. J Exp Med. 2011;208(1):53–66.
   PubMed Web of Science ®Google Scholar
• Satoh K, Fukumoto Y, Sugimura K, et al. Plasma cyclophilin A is a novel biomarker for coronary artery disease. Circ J. 2013;77(2):447–455.
   PubMed Web of Science ®Google Scholar
• Huang CH, Chang CC, Kuo CL, et al. Decrease in plasma cyclophilin A concentration at 1 month after myocardial infarction predicts better left ventricular performance and synchronicity at 6 monthts: a pilot study in patients with ST elevation myocardial infarction. Int J Biol Sci. 2015;11(1):38–47.
   PubMed Web of Science ®Google Scholar
• Kumar A, Takada Y, Boriek AM, et al. Nuclear factor-κB: its role in health and disease. J Mol Med. 2004;82(7):434–448.,
   PubMed Web of Science ®Google Scholar
• Nijmeijer R, Lagrand WK, Lubbers YT, et al. C-reactive protein activates complement in infarcted human myocardium. Am J Path. 2003;163(1):269–275.
   PubMed Web of Science ®Google Scholar
• Badimon L, Peña E, Arderiu G, et al. C-Reactive Protein in atherothrombosis and angiogenesis. Front Immunol. 2018;9:430.
   PubMed Web of Science ®Google Scholar
• Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319–328.
   PubMed Web of Science ®Google Scholar
• Solheim S, Helseth R, Hoffmann P, et al. The profile of circulating pentraxin 3 after PCI in patients with acute myocardial infarction or angina pectoris. Eur Heart J. 2013;34:P5564.
   Google Scholar
• Liu S, Huo Y, Jia X, et al. Effects of ischemic postconditioning on expression of pentraxin-related protein 3 and neutrophil CD11b in the plasma of patients with acute myocardial infarction after percutaneous coronary intervention. Pak J Med Sci. 2016;32:427–430.
   PubMed Web of Science ®Google Scholar
• Zhang H, Sunnarborg S, McNaughton K, et al. Heparin-binding EGF-like growth factor signaling in flow-induced arterial remodeling. Circ Res. 2008;102(10):1275–1285.
   PubMed Web of Science ®Google Scholar
• Lee K, Park J, Lee S, et al. HB-EGF induced delayed STAT3 activation via NF-κB mediated IL-6 secretion in vascular smooth muscle cell. Biochim Bioophys Acta. 2007;1773(11):1637–1644.
   PubMed Web of Science ®Google Scholar
• Tamis-Holland JE, Jneid H. Myocardial infarction with nonobstructive coronary arteries (MINOCA): It's time to face reality! J Am Heart Assoc. 2018;28:e009635.
   Google Scholar
• Ciliberti G, Coiro S, Tritto I, et al. Predictors of poor clinical outcomes in patients with acute myocardial infarction and non-obstructed coronary arteries (MINOCA). Int J Cardiol. 2018;267:41–45.
   PubMed Web of Science ®Google Scholar